Inhalation

INH1024

Issue link: https://www.e-digitaleditions.com/i/1527415

Contents of this Issue

Navigation

Page 24 of 38

Inhalation OctOber 2024 23 (Ph. Eur.), United States Pharmacopoeia (USP) and Japanese Pharmacopoeia (JP), define public quality standards (i.e., analytical procedure, sample size and acceptance criteria) that a drug product is expected to meet if tested at time of manufacture and throughout the registered shelf-life. is article discusses how quality standards defined as "A specified portion (e.g., 90%) of the product attribute should fall within a specified range (e.g., 80-120%) of the labeled claim of that attribute" can provide a better way to establish product spec- ifications. Note that this is not related to sample size; it is the true characteristic of the entire popu- lation. Specific statistical tests can then be designed and adjusted to a given stage of a product's lifecycle (from early product development and characteriza- tion to commercial manufacturing), so that quality control (QC) tests or batch release tests are in fact only demonstrating that the quality standard has been met with a specified level of confidence, confirming the quality that had been built-in through the appro- priate design and implementation of the process. The current way of working Historically, the pharmaceutical industry has relied on published regulatory guidances and pharmaco- peial standards to set batch release acceptance criteria for critical quality attributes. However, acceptance criteria are still often based on subjective judgment assessed against acceptance limits derived from his- torical process capability data. ere is no disagreement between regulators and manufacturers regarding the important role that clin- ically relevant specifications could play in assuring patients receive high-quality drug products that are free of contamination, reproducibly deliver the ther- apeutic benefit promised in the label and are readily available to patients [4]. ere is also no disagree- ment that the specification limits should have some clinical significance, instead of process capability or manufacturing process control limits. However, there is concern by all industry stakeholders about what it will take to establish clinically relevant limits based on test results obtained from analytical meth- ods proven to have a predictive in vitro/in vivo (IVIV) relationship as well as how to establish product qual- ity limits, in the absence of an IVIV correlation, that have some quantitative relationship with the charac- teristics associated with acceptable and/or unaccept- able clinical performance. Although, this article specifically discusses the lim- itations and impact of establishing a quality standard like that recommended in the US FDA's draft guid- ance for MDIs and DPIs to serve as registered prod- uct specifications, the impact extends to all types of medicinal products across all health authority regions. For many product quality attributes, regional phar- macopoeias, such as the European Pharmacopoeia Figure 1 ICH Q10 Product Lifecycle Model (PLM) QTPP = Quality Target Product Profile; CMA = Critical Material Attributes; CPP = Critical Process Parameters; CQA = Critical Quality Attributes Quality PLM Stage 1 PLM Stage 2 PLM Stage 3 PLM Stage 4 Pharmaceutical Development Label Claim: Target Product Profile Product Quality Requirements: QTPP Product Development: Specifications Technology Transfer Process Design: CMAs, CPPs & CQAs Traditional Control Strategy Enhanced Control Strategy Product Discontinuation Document & Sample Retention Product Complaint Handling Product Stability Assessment Commercial Manufacture Confirm, Maintain & Verify Process Performance, Product Quality Continual Improvement

Articles in this issue

view archives of Inhalation - INH1024